MET28 Antibody

What is Med28 and why is it significant in cancer research?

Med28 was initially identified as an endothelial-derived gene-1 (EG-1) in endothelial cells stimulated with tumor-conditioned medium . It functions as a subunit of the mammalian mediator complex that regulates RNA polymerase II transcribed genes. Med28 has gained research interest because its overexpression increases proliferation via activation of extracellular signal-regulated kinase (ERK), and it has been shown to promote tumor formation in nude mice . Elevated Med28 expression has been correlated with poor prognosis in breast cancer patients, making it an important target for cancer research .

What types of Med28 antibodies are available for research?

Four monoclonal antibodies against Med28 have been successfully generated and characterized: 3B2, 4F11, 9G5, and 10D4 . These antibodies are IgG1 kappa isotype and have been validated for various applications including Western blotting, immunoprecipitation, immunofluorescence, and immunohistochemistry . Previously, only polyclonal antibodies were available, which had limitations regarding non-specific signals in certain applications .

What are the primary applications of Med28 antibodies in research?

Med28 antibodies are valuable tools for:

• Detecting endogenous and exogenous Med28 in Western blot analyses

• Immunoprecipitation of both endogenous and overexpressed Med28

• Visualizing cellular localization through immunofluorescence microscopy

• Evaluating Med28 expression in tissue samples via immunohistochemistry

• Studying protein-protein interactions in Med28-mediated regulatory networks

How should I optimize Western blot protocols using Med28 antibodies?

For optimal Western blot results with Med28 antibodies, consider the following methodology:

• Sample preparation: Extract proteins from cells (e.g., Raw264.7, HEK293) using standard lysis buffers

• Gel selection: Use 15% SDS-PAGE for optimal resolution of Med28 (~22 kDa)

• Transfer conditions: Standard transfer protocols are effective for Med28

• Blocking: Use standard blocking solutions (typically 5% non-fat milk or BSA)

• Primary antibody dilution: Validate optimal dilution for each clone (3B2, 4F11, 9G5, 10D4)

• Detection: Both endogenous Med28 (~22 kDa) and tagged versions (e.g., myc-Med28, GFP-Med28 at ~45 kDa) are detectable with these antibodies

What protocol is recommended for immunoprecipitation of Med28?

For effective immunoprecipitation of Med28:

• Prepare protein extracts (1 mg for endogenous IP, 0.2 mg for exogenous IP from transfected cells)

• Incubate extracts with 2 μg of purified Med28 IgG for 4 hours

• Add protein G agarose and incubate for an additional 2 hours

• Wash precipitates thoroughly to remove non-specific binding

• Elute bound proteins and analyze by SDS-PAGE

• Detect using a different Med28 antibody clone (e.g., 9G5) for confirmation

All four Med28 monoclonal antibody clones have demonstrated successful immunoprecipitation of both endogenous Med28 (~22 kDa) and overexpressed forms like GFP-Med28 (~45 kDa) .

How does Med28 subcellular localization vary across cell types and cancer tissues?

Immunofluorescence and immunohistochemical studies using Med28 monoclonal antibodies have revealed that Med28 localizes to both the cytoplasm and nucleus in cell lines such as MCF-7 . In human breast cancer tissues, Med28 was found to be predominantly localized in the nucleus with some cytoplasmic expression . This dual localization pattern supports Med28's multiple proposed functions in both transcriptional regulation (nuclear) and signal transduction (cytoplasmic). Researchers should consider evaluating both nuclear and cytoplasmic expression patterns when studying Med28 in different tissue contexts .

What are the methodological differences between detecting Med28 in cell culture versus tissue samples?

The approach to detecting Med28 differs significantly between cell culture and tissue applications:

For cell culture (immunofluorescence):

• Cells should be seeded on coverslips and fixed appropriately

• All four Med28 antibody clones (3B2, 4F11, 9G5, 10D4) work effectively

• Counterstaining with DAPI helps visualize nuclei and confirm nuclear localization

• Both endogenous and overexpressed Med28 are detectable

For tissue samples (immunohistochemistry):

• Paraffin-embedded tissues should be sectioned (5 μm thickness)

• Endogenous peroxidase quenching with methanol/peroxidase solution is necessary

• Antibody dilution of 1:100 is typically effective

• Clones 3B2, 9G5, and 10D4 are suitable, while 4F11 has been shown to be ineffective for IHC

• DAB detection systems work well for visualization

• Mayer's hematoxylin is recommended for counterstaining

How can Med28 antibodies be used to investigate its role in cancer progression mechanisms?

Med28 antibodies enable several experimental approaches to investigate its role in cancer:

• Expression correlation studies: IHC analysis of patient samples to correlate Med28 expression with clinical outcomes

• Interaction partner identification: IP-MS experiments to identify novel Med28-interacting proteins in cancer cells

• Signaling pathway analysis: Combine with phospho-specific antibodies to monitor ERK activation in response to Med28 modulation

• Functional inhibition studies: Use Med28 antibodies for targeted inhibition experiments (similar to studies showing reduced growth of breast cancer with polyclonal antibodies)

• Subcellular dynamics: Track changes in Med28 localization during cancer progression or in response to treatments

How do monoclonal Med28 antibodies compare to previously used polyclonal antibodies?

The development of monoclonal antibodies against Med28 represents a significant advancement over previously used polyclonal antibodies:

The generation of Med28-specific monoclonal antibodies addresses previous challenges in obtaining high-quality antibodies against this protein, as generating Med28-specific antibodies has been noted to be difficult .

What are the key technical challenges in generating effective antibodies against Med28?

Generating high-quality antibodies against Med28 has proven challenging due to several factors:

• Screening difficulties: Out of 76 initial clones screened by ELISA and immunoblotting, most only recognized recombinant or exogenous Med28, not endogenous Med28

• Background issues: Non-specific background has been a persistent problem, even with rabbit polyclonal antibodies

• Immunization protocol optimization: Successful generation required trials of various immunization protocols and boosting intervals

• Protein preparation challenges: Med28 proteins predominantly formed inclusion bodies when expressed in E. coli, requiring in-chromatography renaturation methods

• Clone selection criteria: Only four hybridomas ultimately recognized both exogenous and endogenous Med28 without showing non-specific bands

How do antibody approaches to MET receptor differ from Med28 antibody applications?

While Med28 and MET are distinct proteins, researchers interested in receptor tyrosine kinase signaling may benefit from understanding the differences in antibody approaches:

MET receptor antibodies like LY2875358 function through:

• Neutralization of HGF binding to MET

• Induction of receptor internalization and degradation

• Inhibition of both ligand-dependent and ligand-independent activation

• Potential therapeutic applications through direct tumor growth inhibition

In contrast, Med28 antibodies primarily serve as research tools for:

• Detection and quantification of Med28 expression

• Studying subcellular localization and protein interactions

• Investigating correlations with disease progression

• Potential targeted inhibition of Med28-mediated functions

Understanding these different mechanisms is important when designing experiments targeting cancer signaling pathways.

What are promising future applications of Med28 antibodies in cancer research?

Med28 antibodies open several avenues for future research:

• Biomarker development: Validation of Med28 as a prognostic or predictive biomarker in various cancer types beyond breast cancer

• Therapeutic targeting: Development of function-blocking antibodies based on the existing monoclonal antibodies

• Mechanistic studies: Investigation of the Med28-mediated regulatory network in tumorigenesis using IP-MS and other antibody-dependent techniques

• In vivo imaging: Development of labeled Med28 antibodies for tumor imaging applications

• Multi-omics integration: Correlation of Med28 protein expression (via antibody detection) with transcriptomic and genomic data

What methodological considerations should be taken when using Med28 antibodies in combination with other molecular techniques?

When integrating Med28 antibodies with other techniques:

• ChIP-seq studies: Consider the dual nuclear/cytoplasmic localization when optimizing chromatin immunoprecipitation protocols

• Proximity labeling: Med28 antibodies can help validate results from BioID or APEX2 proximity labeling experiments

• Live-cell imaging: Consider antibody fragment development for live-cell applications

• Mass spectrometry: Use high-specificity clones like 9G5 for immunoprecipitation prior to MS analysis

• CRISPR studies: Med28 antibodies are essential tools for validating knockout or knockdown efficiency in genetic manipulation studies